Literature DB >> 15467033

A molecular genetic and statistical approach for the diagnosis of dual-site cancers.

Dirk Brinkmann1, Andy Ryan, Ayse Ayhan, W Glen McCluggage, Roger Feakins, Mauro F Santibanez-Koref, Charles A Mein, Simon A Gayther, Ian J Jacobs.   

Abstract

BACKGROUND: Concurrent tumors can be synchronous, independently derived, non-metastatic tumors or metastatic tumors. The prognosis and clinical management of patients with these different concurrent tumor types are different.
METHODS: DNA from normal and tumor tissues of 62 patients with synchronous endometrial and ovarian, bilateral ovarian, or endometrial and bilateral ovarian tumors was analyzed for loss of heterozygosity and microsatellite instability using eight polymorphic microsatellite markers at loci frequently deleted in ovarian and/or endometrial cancers. A statistical algorithm was designed to assess the clonal relationship between the tumors.
RESULTS: The original histopathology reports classified 26 (42%) case patients with single primary tumors and related metastatic lesions and 21 (34%) with independent primary tumors; 15 (24%) were unclassified. Genetic data identified 35 (56%) case patients with single primary tumors and related metastatic lesions, 18 (29%) with independent primary tumors, and nine (15%) that could not be typed. Excluding case patients with histopathology reports for which a clonal relationship was uncertain or was not reported, there was 53% concordance between genetic and histopathology diagnoses. Increasing the stringency of the statistical analysis increased the number of uncertain diagnoses but did not affect the proportion of discordant genetic and histologic diagnoses.
CONCLUSIONS: We have developed a rapid and robust combined genetic and statistical method to establish whether multiple tumors from the same patient represent distinct primary tumors or whether they are clonally related and therefore metastatic. For the majority of case patients, histopathology reports and genetic analyses were in agreement and diagnostic confidence was improved. Importantly, in approximately one-fourth of all case patients, genetic and histopathologic analyses suggested alternative diagnoses. The results suggest that genetic analysis has implications for clinical management and can be performed rapidly as a diagnostic test with paraffin-embedded tissues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15467033     DOI: 10.1093/jnci/djh272

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  6 in total

1.  Statistical tests for clonality.

Authors:  Colin B Begg; Kevin H Eng; Amanda J Hummer
Journal:  Biometrics       Date:  2007-06       Impact factor: 2.571

2.  Separate and combined analysis of successive dependent outcomes after breast-conservation surgery: recurrence, metastases, second cancer and death.

Authors:  Virginie Rondeau; Simone Mathoulin-Pélissier; Lucie Tanneau; Annie J Sasco; Gaétan Macgrogan; Marc Debled
Journal:  BMC Cancer       Date:  2010-12-31       Impact factor: 4.430

3.  Peritoneal Carcinosarcoma and Ovarian Papillary Serous Carcinoma Are the Same Origin: Analysis of TP53 Mutation and Microsatellite Suggests a Monoclonal Origin.

Authors:  Chang Gok Woo; Dae Shik Suh; Joo Young Kim; Chang Ohk Sung; Jene Choi; Kyu-Rae Kim
Journal:  Korean J Pathol       Date:  2014-12-31

4.  Trends and outcomes of women with synchronous endometrial and ovarian cancer.

Authors:  Koji Matsuo; Hiroko Machida; Erin A Blake; Laura L Holman; Bobbie J Rimel; Lynda D Roman; Jason D Wright
Journal:  Oncotarget       Date:  2018-06-19

5.  A rare case of synchronous right ovarian clear cell carcinoma and an incidental left ovarian endometrioid carcinoma with immunohistochemical study.

Authors:  Siddhi G S Khandeparkar; Sanjay D Deshmukh; Hemant S Lekawale; Amit Bhoge; Ansari Tabassum Parveen Maqbool Ahmed
Journal:  J Midlife Health       Date:  2014-04

Review 6.  Potential for Mitochondrial DNA Sequencing in the Differential Diagnosis of Gynaecological Malignancies.

Authors:  Anna Myriam Perrone; Giulia Girolimetti; Martina Procaccini; Lorena Marchio; Alessandra Livi; Giulia Borghese; Anna Maria Porcelli; Pierandrea De Iaco; Giuseppe Gasparre
Journal:  Int J Mol Sci       Date:  2018-07-13       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.